Isradipine augmentation of virtual reality cue exposure therapy for tobacco craving: a triple-blind randomized controlled trial.

MLA

Young, Cara C., et al. “Isradipine Augmentation of Virtual Reality Cue Exposure Therapy for Tobacco Craving: A Triple-Blind Randomized Controlled Trial.” Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 49, no. 11, Oct. 2024, pp. 1711–18. EBSCOhost, https://doi.org/10.1038/s41386-024-01872-9.

APA

Young, C. C., Papini, S., Minami, H., Morikawa, H., Otto, M. W., Roache, J. D., & Smits, J. A. J. (2024). Isradipine augmentation of virtual reality cue exposure therapy for tobacco craving: a triple-blind randomized controlled trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 49(11), 1711–1718. https://doi.org/10.1038/s41386-024-01872-9

Chicago

Young, Cara C, Santiago Papini, Haruka Minami, Hitoshi Morikawa, Michael W Otto, John D Roache, and Jasper A J Smits. 2024. “Isradipine Augmentation of Virtual Reality Cue Exposure Therapy for Tobacco Craving: A Triple-Blind Randomized Controlled Trial.” Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology 49 (11): 1711–18. doi:10.1038/s41386-024-01872-9.